Risankizumab for Ulcerative Colitis
Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis.
Related Content:
Monoclonal Antibody Risankizumab for Ulcerative Colitis
Risankizumab for Ulcerative Colitis
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.